These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 3161318

  • 1. Effects of amrinone on myocardial energetics in severe congestive heart failure.
    Baim DS.
    Am J Cardiol; 1985 Jul 22; 56(3):16B-18B. PubMed ID: 3161318
    [Abstract] [Full Text] [Related]

  • 2. Effect of phosphodiesterase inhibition on myocardial oxygen consumption and coronary blood flow.
    Baim DS.
    Am J Cardiol; 1989 Jan 03; 63(2):23A-26A. PubMed ID: 2521267
    [Abstract] [Full Text] [Related]

  • 3. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2.
    Colucci WS, Wright RF, Braunwald E.
    N Engl J Med; 1986 Feb 06; 314(6):349-58. PubMed ID: 2418353
    [No Abstract] [Full Text] [Related]

  • 4. Non-glycoside, non-catecholamine inotropic agents in the treatment of congestive heart failure.
    Tommaso CL.
    Am J Med; 1986 Feb 28; 80(2B):36-9. PubMed ID: 3004210
    [No Abstract] [Full Text] [Related]

  • 5. Effects of several newer cardiotonic drugs on cardiac cyclic AMP metabolism.
    Ahn HS, Eardley D, Watkins R, Prioli N.
    Biochem Pharmacol; 1986 Apr 01; 35(7):1113-21. PubMed ID: 2421728
    [Abstract] [Full Text] [Related]

  • 6. Clinical effects of intravenous amrinone in patients with congestive heart failure.
    Goldstein RA.
    Circulation; 1986 Mar 01; 73(3 Pt 2):III191-5. PubMed ID: 3510775
    [Abstract] [Full Text] [Related]

  • 7. [New positive inotropic drugs].
    Lehot JJ.
    Ann Fr Anesth Reanim; 1991 Mar 01; 10(1):62-9. PubMed ID: 1672585
    [No Abstract] [Full Text] [Related]

  • 8. The new inotropic phosphodiesterase inhibitors.
    el Allaf D, D'Orio V, Carlier J.
    Arch Int Physiol Biochim; 1984 Nov 01; 92(4):S69-79. PubMed ID: 6085243
    [Abstract] [Full Text] [Related]

  • 9. The inotropic effects of amrinone and milrinone on neonatal and young canine cardiac muscle.
    Binah O, Sodowick B, Vulliemoz Y, Danilo P, Rosen M.
    Circulation; 1986 Mar 01; 73(3 Pt 2):III46-51. PubMed ID: 3002663
    [Abstract] [Full Text] [Related]

  • 10. [Dose-dependent effect of amrinone on hemodynamics, myocardial circulation and myocardial energy requirement. An experimental study].
    Veit S, Brückner JB, Vogt K, Wagner R, Hess W.
    Z Kardiol; 1985 Feb 01; 74(2):76-84. PubMed ID: 3993153
    [Abstract] [Full Text] [Related]

  • 11. Biochemical mechanisms for the inotropic effect of the cardiotonic drug milrinone.
    Earl CQ, Linden J, Weglicki WB.
    J Cardiovasc Pharmacol; 1986 Feb 01; 8(4):864-72. PubMed ID: 2427830
    [Abstract] [Full Text] [Related]

  • 12. [Effects of amrinone on renal blood flow and cardiac function, in comparison with those of milrinone and olprinone, in anesthetized dog].
    Fujishima K, Yamamoto A, Hachisu M.
    Nihon Yakurigaku Zasshi; 1998 Dec 01; 112(6):371-80. PubMed ID: 10202762
    [Abstract] [Full Text] [Related]

  • 13. [Effects of amrinone, a new non-digitalic positive inotropic agent, on the efficiency and coronary circulation of the heart].
    Bárcenas L, Kabela E.
    Arch Inst Cardiol Mex; 1984 Dec 01; 54(5):431-40. PubMed ID: 6517640
    [Abstract] [Full Text] [Related]

  • 14. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle.
    Endoh M, Yanagisawa T, Taira N, Blinks JR.
    Circulation; 1986 Mar 01; 73(3 Pt 2):III117-33. PubMed ID: 2417745
    [Abstract] [Full Text] [Related]

  • 15. The improvement of cardiac performance by amrinone, a new cardiotonic drug, in an experimental failing heart preparation of the dog.
    Satoh K, Maruyama M, Taira N.
    Jpn Heart J; 1982 Nov 01; 23(6):975-80. PubMed ID: 7161881
    [No Abstract] [Full Text] [Related]

  • 16. Effects of milrinone on coronary hemodynamics and myocardial energetics in patients with congestive heart failure.
    Monrad ES, Baim DS, Smith HS, Lanoue A, Brauwald E, Grossman W.
    Circulation; 1985 May 01; 71(5):972-9. PubMed ID: 3986984
    [Abstract] [Full Text] [Related]

  • 17. Milrinone, a new agent for the treatment of congestive heart failure.
    Hasegawa GR.
    Clin Pharm; 1986 Mar 01; 5(3):201-5. PubMed ID: 3514085
    [Abstract] [Full Text] [Related]

  • 18. Pharmacology of the bipyridines: amrinone and milrinone.
    Alousi AA, Johnson DC.
    Circulation; 1986 Mar 01; 73(3 Pt 2):III10-24. PubMed ID: 2417744
    [Abstract] [Full Text] [Related]

  • 19. Comparative effects of R 80122, enoximone, and milrinone on left ventricular phosphodiesterase isoenzymes in vitro and on contractility of normal and stunned myocardium in vivo in dogs.
    Vandeplassche GM, Hermans CF, de Chaffoy de Courcelles DR, D'Aubioul JA, Wouters LJ, De Clerck FF.
    J Cardiovasc Pharmacol; 1992 May 01; 19(5):714-22. PubMed ID: 1381769
    [Abstract] [Full Text] [Related]

  • 20. A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts.
    Zausig YA, Stowe DF, Zink W, Grube C, Martin E, Graf BM.
    Anesth Analg; 2006 Jun 01; 102(6):1646-52. PubMed ID: 16717301
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.